Clinical Trials Browser

Phase 1/2 × Biliary Tract Neoplasms × derazantinib × Clear all

NCT01752920 2023-06-05

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Phase 1/2 Completed

119 enrolled 15 charts

Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Neoplasms, Cholangiocarcinoma